MX2023007741A - Formulaciones de upadacitinib de liberacion prolongada. - Google Patents
Formulaciones de upadacitinib de liberacion prolongada.Info
- Publication number
- MX2023007741A MX2023007741A MX2023007741A MX2023007741A MX2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A MX 2023007741 A MX2023007741 A MX 2023007741A
- Authority
- MX
- Mexico
- Prior art keywords
- upadacitinib
- extended release
- formulations
- solid dosage
- pharmaceutically acceptable
- Prior art date
Links
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title abstract 3
- 229950000088 upadacitinib Drugs 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063131564P | 2020-12-29 | 2020-12-29 | |
| PCT/US2021/065443 WO2022147073A1 (en) | 2020-12-29 | 2021-12-29 | Extended release upadacitinib formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007741A true MX2023007741A (es) | 2023-09-15 |
Family
ID=82261098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007741A MX2023007741A (es) | 2020-12-29 | 2021-12-29 | Formulaciones de upadacitinib de liberacion prolongada. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20240316040A1 (enExample) |
| EP (1) | EP4271380A4 (enExample) |
| JP (1) | JP2024501051A (enExample) |
| KR (1) | KR20230127266A (enExample) |
| AU (1) | AU2021411506A1 (enExample) |
| CA (1) | CA3206839A1 (enExample) |
| MX (1) | MX2023007741A (enExample) |
| WO (1) | WO2022147073A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909160B (zh) * | 2019-05-09 | 2024-05-28 | 苏州鹏旭医药科技有限公司 | 一种乌帕替尼盐类化合物及其制备方法 |
| CA3248817A1 (en) * | 2022-01-20 | 2023-07-27 | Renata Pharmaceutical (Ireland) Limited | Extended-release pharmaceutical composition of Upadacitinib |
| EP4583877A1 (en) * | 2022-09-09 | 2025-07-16 | Intas Pharmaceuticals Ltd. | Upadacitinib formulation |
| CN117357492A (zh) * | 2023-10-31 | 2024-01-09 | 苏州天马医药集团天吉生物制药有限公司 | 一种乌帕替尼缓释片剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06003453A (es) * | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Barra de empuje oros para el suministro controlado de agentes activos. |
| US20090099154A1 (en) * | 2005-06-29 | 2009-04-16 | Panacea Biotec Ltd. | Pharmaceutical Sustained Release Compositions and Processes Thereof |
| JP5052051B2 (ja) * | 2006-06-16 | 2012-10-17 | トーアエイヨー株式会社 | 腸溶性顆粒剤及びその製造方法 |
| US20140271892A1 (en) * | 2013-03-15 | 2014-09-18 | Mcneil-Ppc, Inc. | Phenylephrine resinate particles having good auc |
| AU2018230500B2 (en) * | 2017-03-09 | 2024-03-07 | Abbvie Inc. | Methods of treating Crohn's disease and ulcerative colitis |
| AU2018312349A1 (en) * | 2017-08-01 | 2020-02-06 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| WO2020115212A1 (en) * | 2018-12-05 | 2020-06-11 | Lek Pharmaceuticals D.D. | Crystalline phosphate salt of selective jak1 inhibitor upadacitinib |
-
2021
- 2021-12-29 EP EP21916388.8A patent/EP4271380A4/en active Pending
- 2021-12-29 KR KR1020237025347A patent/KR20230127266A/ko active Pending
- 2021-12-29 JP JP2023539796A patent/JP2024501051A/ja active Pending
- 2021-12-29 MX MX2023007741A patent/MX2023007741A/es unknown
- 2021-12-29 CA CA3206839A patent/CA3206839A1/en active Pending
- 2021-12-29 US US18/259,744 patent/US20240316040A1/en active Pending
- 2021-12-29 AU AU2021411506A patent/AU2021411506A1/en active Pending
- 2021-12-29 WO PCT/US2021/065443 patent/WO2022147073A1/en not_active Ceased
-
2025
- 2025-01-17 US US19/027,247 patent/US20250161302A1/en not_active Abandoned
- 2025-09-09 US US19/323,495 patent/US20260007661A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022147073A1 (en) | 2022-07-07 |
| JP2024501051A (ja) | 2024-01-10 |
| AU2021411506A9 (en) | 2024-09-26 |
| KR20230127266A (ko) | 2023-08-31 |
| US20240316040A1 (en) | 2024-09-26 |
| US20250161302A1 (en) | 2025-05-22 |
| CA3206839A1 (en) | 2022-07-07 |
| EP4271380A4 (en) | 2025-01-22 |
| US20260007661A1 (en) | 2026-01-08 |
| AU2021411506A1 (en) | 2023-07-13 |
| EP4271380A1 (en) | 2023-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007741A (es) | Formulaciones de upadacitinib de liberacion prolongada. | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| EP4527467A3 (en) | Pharmaceutical formulations | |
| MX2015016112A (es) | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. | |
| PH12019501076A1 (en) | Pharmaceutical formulations | |
| GB202202470D0 (en) | Bio-ink formulations, bio-printed corneal lenticule, and applications thereof | |
| MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| HK1254343A1 (zh) | 药物制剂 | |
| MY209101A (en) | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof | |
| SG10201902407PA (en) | Injectable microparticles for hyper-localized release of therapeutic agents | |
| MX2018011799A (es) | Formas de dosificacion de liberacion prolongada disuasivas de abuso. | |
| GB2581874B (en) | Polyaryletherketone copolymer material, manufacture and use thereof | |
| ZA202104704B (en) | Pharmaceutical composition | |
| MX2018008868A (es) | Composiciones farmaceuticas que contienen glucomanano con liberacion extendida y propiedades disuasivas de abuso. | |
| MY208261A (en) | Oral pharmaceutical composition | |
| PH12021552643A1 (en) | Solid pharmaceutical composition comprising tlr7 agonist | |
| EP4461361A3 (en) | Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease | |
| WO2018187698A3 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
| MX2020011321A (es) | Profármacos de estrógeno y métodos de administración de profármacos de estrógeno. | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| MX2021002459A (es) | Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata. | |
| WO2015100370A3 (en) | Sustained release depot formulations of therapeutic proteins, and uses thereof | |
| WO2007016350A3 (en) | Modified release tablet formulations with enhanced mechanical properties | |
| MX2021002686A (es) | Formulacion controlada de liberacion de farmacos. | |
| IN2013MU03370A (enExample) |